MHC class I-presented Ebola virus or Marburg virus nucleocapsid protein epitope (Null (no widely accepted, standardized abbreviation))

These are short peptide fragments (typically 8–10 amino acids) derived from the nucleocapsid protein of the Ebola or Marburg virus, which are processed by the host cell's proteasome and presented on the cell surface by MHC class I molecules[4][5][7]. Presentation of these epitopes enables recognition by cytotoxic CD8+ T cells, which can then destroy infected cells before viral replication increases. These epitopes are of significant interest for the design of T cell-based vaccines and immunotherapeutics for Ebola and Marburg virus diseases[3]. Further detail: - The nucleocapsid protein (NP) is a structural protein essential for virus assembly and genome replication in both Ebola and Marburg viruses[1]. - Hundreds of distinct MHC class I epitopes can be generated across different viral strains and human HLA types; no single epitope is universally dominant[3]. - Therapeutic vaccine development often identifies “best” epitopes for inclusion based on common HLA alleles and immunogenicity studies in animal models and humans[3].

Other names

MHC class I epitope of Ebola nucleocapsid proteinMHC class I epitope of Marburg nucleocapsid proteinEbola nucleoprotein-derived MHC I epitopeMarburg nucleoprotein-derived MHC I epitopeEbola/Marburg NP CTL epitope

Induction of cytotoxic CD8+ T cell response recognizing and killing cells infected with Ebola or Marburg virus via presentation of nucleocapsid epitopes on MHC class I molecules[4][5].